All news

Charles River to buy Frontage's US bioanalysis assets for about $470 million in take-private deal

Pharmaceutical Technology · · AI-summarised by FinFlash

Charles River Laboratories agreed to acquire Frontage Holdings' bioanalysis and DMPK operations in Exton, Pennsylvania, for roughly $470 million in cash plus earn-outs of up to $75 million. The units generated about 40% of Frontage's $256.7 million 2025 revenue and employ nearly 340 staff. Charles River joins a consortium with Hongkong Tigermed and Frontage chairman Song Li to privatise and delist Frontage from Hong Kong. Closing is expected in the first half of 2027.

So What?

Adds clinical bioanalysis capacity to Charles River funded by cash and credit lines; the take-private offer is a catalyst for Frontage and Tigermed shares in Hong Kong.

Read original source

CRL company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.